Nishiyama, Hiroyuki
Tanaka, Yu
Hamada, Masahiro
Ozaki, Masahiko
Minegishi, Toshihiko
Ito, Yuichiro
Maekawa, Shinichiroh
Yamamoto, Nobuyuki
Article History
Received: 10 January 2023
Accepted: 8 May 2023
First Online: 20 June 2023
Declarations
:
: This post-marketing surveillance conformed to the provisions of the Declaration of Helsinki and was conducted based on the Good Post-Marketing Study Practice authorized by the Ministry of Health, Labour and Welfare of Japan (Ordinance No. 171, 2004). The ordinance exempts the requirement of ethical review and patients’ informed consent in post-marketing surveillance.
: Not applicable.
: HN has received all support for the present manuscript from MSD; grants or contracts from Ono Pharmaceutical, Astellas Pharma, Bayer, and Chugai Pharmaceutical through his own institution; consulting fees from Ono Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and MSD; and payment or honoraria from Olympus, Astellas Pharma, Merck Biopharma, and MSD. YT was an employee of MSD at the time of the study. MH is an employee of MSD; and holds stock or stock options in Merck & Co., and Organon & Co. MO is an employee of MSD and holds stock or stock options in Merck & Co. TM is an employee of MSD and holds stock or stock options in Merck and GlaxoSmithKline. YI is an employee of MSD; and holds stock or stock options in Merck & Co., and Bayer AG. SM is an employee of MSD and holds stock or stock options in Merck. NY has received grants or contracts from MSD, AstraZeneca, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical., Pfizer, Amgen, Janssen Pharmaceutical, Toppan Printing, Terumo, and Boehringer-Ingelheim through his own institution; consulting fees from AstraZeneca, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer-Ingelheim, Novartis, Bristol-Myers Squibb, Nippon Kayaku, Life Technologies Japan, Amgen, Guardant Health Japan, and Janssen Pharmaceutical; honoraria from MSD, AstraZeneca, Ono Pharmaceutical, Thermo Fisher Scientific, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer-Ingelheim, Novartis, Pfizer, Bristol-Myers Squibb, Nippon Kayaku, GlaxoSmithKline, Sanofi, Hisamitsu Pharmaceutical, and Merck Biopharma; and has participated in a data safety monitoring or advisory board for MSD, AstraZeneca, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Boehringer-Ingelheim, and Pfizer.